© Reuters. Workers of Teva Pharmaceutical Industries stand at the entrance to their facility in Ashdod, Israel

(Reuters) – Teva Pharmaceutical (NYSE:) Industries Ltd (TA:) said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc (O:) over its generic Cinacalcet HCl product.

The Israel-based drugmaker has also agreed to stop selling the generic product until its license date in mid-year 2021, or earlier under certain circumstances https://reut.rs/2BUnEad.

Teva said it recently received approval for the generic product and launched it in the United States.

Cinacalcet hydrochloride is approved for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis and for the treatment of higher levels of calcium in adults with parathyroid carcinoma.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Teva, Amgen end dispute over generic Cinacalcet HCl tablets By Reuters


Please enter your comment!
Please enter your name here